As part of a four-year programme worth £5.4M, awarded by the Norwegian Research Council, researchers are employing novel approaches to synthesise and test alginate molecules (components of seaweed) to design a new generation of drug compounds capable of improving the effectiveness of antibiotics.
Research conducted by the universities has shown that these seaweed compounds are capable of combating multi-drug resistant infections and can change the physical structure of sputum (phlegm) in diseased patients.
Harnessing this knowledge, scientists have developed a new inhalation therapy that is being tested on cystic fibrosis patients with the aim of improving their breathing – the condition affects 10,000 people in the UK alone and leads to sufferers being hospitalised up to three times a year.
The new therapeutic could also be used in other more common respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), which is reported to affect over 1 million sufferers in the UK.
Studies are also paving the way towards improved treatment of chronic non-healing skin wounds and multi-drug resistant infections, such as MRSA. These seaweed compounds are also effective against organisms that cause more benign conditions like gum disease.
Project leader Professor David Thomas from the School of Dentistry said:
“This is a particularly exciting project that is proving we are able to derive material from the natural world with powerful abilities to modify bacterial behaviour and sputum structure, which can be applied to the development of alternative treatment approaches for challenging and hard to treat diseases. Now, more than ever in an aging population, we must to look for new ways of managing disease where conventional approaches are proving increasingly inadequate.”
Alginates are normal components of seaweed, like laver-bread, and have been used as gelling agents in food and healthcare industries for many years. However, the alginate being studied in this programme of research has never been used before to combat infectious diseases.